Study identifies novel target for pediatric neuroblastoma

Posted date


Study Title: The KAT module of the SAGA complex maintains the oncogenic gene expression program in MYCN-amplified neuroblastoma

Publication: Science Advances

Dana-Farber Cancer Institute authors: Clare F. Malone, PhD; Nathaniel W. Mabe, PharmD, PhD; Kimberly Stegmaier, MD


Researchers at Dana-Farber Cancer Institute have identified a protein complex that is required for the growth of a high-risk form of childhood brain cancer called MYCN-amplified neuroblastoma. The MYCN gene is amplified in approximately 20-25% of childhood neuroblastoma cases. MYCN produces a transcription factor called MYCN that turns on a cancer-driving gene expression program. Suppressing this oncogenic program by inhibiting MYCN directly is difficult, so this team used functional genomic screens to identify other potential ways to suppress the program. They discovered that expression of the MYCN program depends on the SAGA complex, which is an epigenetic regulator. They also found that the SAGA complex can be inhibited pharmacologically, making it an attractive potential target for future drug development in neuroblastoma.


Neuroblastoma is the most common childhood solid tumor and accounts for a disproportionately high number of cancer-related deaths in children. This research identifies a potential novel approach to treatment of MYCN-amplified neuroblastoma, a high-risk form of the disease which accounts for approximately 20-25% of childhood neuroblastoma cases.


Helen Gurley Brown Presidential Initiative, National Institutes of Health, V Foundation, and Friends for Life

News Category
Brain Tumors, Childhood
Related Doctors and Researchers

Media Contacts

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email

The Media Team cannot respond to patient inquiries. For more information, please see Contact Us.


Kimberly Stegmaier, MD